Abstract
The concept that atherosclerosis is an inflammatory disease goes back to the middle of the nineteenth century when Rudolf Virchow stated that “he felt no hesitation in admitting an inflammation of the inner arterial coat to be the starting point of the so-called atheromatous degeneration”1 and Carl von Rokitansky considered “chronic inflammation of the cellular sheet of the diseased vessel to be a secondary consecutive appearance which associated itself with the already established deposit.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Virchow RLK. Cellular Pathology. London: John Churchill; 1859.
Rokitansky C. A Manual of Pathological Anatomy. Philadelphia: Blanchard & Lea; 1855.
Ross R, Glomset JA. The pathogenesis of atherosclerosis. N Engl J Med. 1976;295:369–377.
Ross R, Glomset JA. The pathogenesis of atherosclerosis. N Engl J Med. 1976;295:420–425.
Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685–1695.
Andersson J, Libby P, Hansson GK. Adaptive immunity and atherosclerosis. Clin Immunol. 2010;134(1):33–46.
Van Campenhout A, Golledge J. Osteoprotegerin, vascular calcification and atherosclerosis. Atherosclerosis. 2009;204:321–329.
Danesh J et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350:1387–1397.
Fibrinogen Studies Collaboration et al. Plasma fibrinogen and the risk of major cardiovascular diseases and non-vascular mortality: meta-analysis of individual data for 151,649 adults in 31 prospective studies. JAMA. 2005;294:1799–1809.
Libby P. Role of inflammation in atherosclerosis associated with rheumatoid arthritis. Am J Med. 2008;121:S21-S31.
Kiechl S et al. Chronic infections and the risk of carotid atherosclerosis. Prospective results from a large population study. Circulation. 2001;103:1064–1070.
Knoflach M, Kiechl S, Mair A, Willeit J, Wick G. Allergic rhinitis, asthma and atherosclerosis in the Bruneck and ARMY Studies. Arch Intern Med. 2005;165:2521–2526.
Sun J et al. Mast cells promote atherosclerosis by releasing proinflammatory cytokines. Nat Med. 2007;13:719–724.
Kiechl S et al. Active and passive smoking, chronicinfections and the risk of carotid atherosclerosis. Prospective results from the Bruneck Study. Stroke. 2002;33:2170–2176.
Mazzone T, Chait A, Plutzky J. Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies. Lancet. 2008;371:1800–1809.
Markus H et al. Pro-inflammatory genes variants predispose to carotid and femoral artery atherosclerosis in the presence of pro-inflammatory risk factors and chronic infection. Stroke. 2006;37:2253–2259.
McPherson R et al. A common allele on chromosome 9 associated with coronary heart disease. Science. 2007;316:1488–1491.
Ye S, Willeit J, Kronenberg F, Xu Q, Kiechl S. Association of genetic variation on chromosome 9p21 with susceptibility and progression of atherosclerosis – a prospective study. J Am Coll Cardiol. 2008;52:378–384.
Wiedermann CI et al. Association of endotoxemia with carotid atherosclerosis and cardiovascular disease. Prospective results from the Bruneck study. J Am Coll Cardiol. 1999;34:1975–1981.
Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med. 1989;320:915–924.
Wick G, Knoflach M, Xu Q. Autoimmune and inflammatory mechanisms in atherosclerosis. Annu Rev Immunol. 2004;22:361–403.
Kiechl S, Wiedermann CJ, Willeit J. TLR-4 and disease. Ann Med. 2003;35:165–171.
Kiechl S et al. Toll-like receptor 4 polymorphisms and atherogenesis in humans. N Engl J Med. 2002;347:185–192.
Björkbacka H et al. Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat Med. 2004;10:416–421.
Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med. 1992;326:242–250.
Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N Engl J Med. 1992;326:310–318.
Kiechl S, Willeit J. The natural course of atherosclerosis. Part I: incidence and progression. Arterioscler Thromb Vasc Biol. 1999;19:1484–1490.
Kiechl S, Willeit J. The natural course of atherosclerosis. Part II: vascular remodeling. Arterioscler Thromb Vasc Biol. 1999;19:1491–1498.
Willeit J et al. Distinct risk profiles of early and advanced atherosclerosis. Prospective results from the Bruneck study. Arterioscler Thromb Vasc Biol. 2000;20:529–537.
Kiechl S, Willeit J, Egger G, Poewe W, Oberhollenzer F. Body iron stores and the risk of carotid atherosclerosis. Prospective results from the Bruneck study. Circulation. 1997;96:3300–3307.
Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med. 1987;316:1371–1375.
Tsimikas S et al. Lipoprotein-associated phospholipase A2 activity, ferritin levels, metabolic syndrome and 10-year cardiovascular and non-cardiovascular mortality: results from the Bruneck study. Eur Heart J. 2009;30:107–115.
Kiechl S et al. Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity and 10-year cardiovascular outcomes: prospective results from the Bruneck study. Arterioscler Thromb Vasc Biol. 2007;27:1788–1795.
The Emerging Risk Factors Collaboration. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke and nonvascular mortality. Individual data analysis of 121,944 participants from 34 cohorts. JAMA. 2009;302:412–423.
Zacharski LR et al. Reduction of iron stores and cardiovascular outcomes in patients with peripheral arterial disease: a randomized controlled trial. JAMA. 2007;297:603–610.
Davidson MH et al. Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines. Am J Cardiol. 2008;101:51F-57F.
Kiechl S et al. The OPG/RANK/RANKL system – a bone key to vascular disease. Expert Rev Cardiovasc Ther. 2006;4:801–811.
Collin-Osdoby P. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ Res. 2004;95:1046–1057.
Kiechl S et al. Soluble receptor activator of nuclear factor-κB ligand (RANKL) and risk of cardiovascular disease. Circulation. 2007;116:385–391.
Kiechl S et al. Osteoprotegerin is a risk predictor of progressive atherosclerosis and cardiovascular disease. Circulation. 2004;109:2175–2180.
Afzal AR et al. Common CCR5-del32 frameshift mutation associated with serum levels of inflammatory markers and cardiovascular disease risk in the Bruneck population. Stroke. 2008;39:1972–1978.
Willeit J et al. The Marburg I polymorphism of factor VII activating protease: a prominent risk predictor of arterial thrombosis. Circulation. 2003;107:667–670.
Knoflach M et al. Cardiovascular risk factors and atherosclerosis in young women – ARFY study (Atherosclerosis Risk-Factors in Female Youngsters). Stroke. 2009;40:1063–1069.
Knoflach M et al. Vascular risk factors and atherosclerosis in young males – ARMY study (Atherosclerosis Risk-Factors in Male Youngsters). Circulation. 2003;108:1064–1069.
Xu Q et al. Serum soluble heat shock protein 60 is elevated in subjects with atherosclerosis in a general population. Circulation. 2000;102:14–20.
Xu Q et al. Association of serum antibodies to heat-shock protein 65 with carotid atherosclerosis. Lancet. 1993;341:255–259.
Brouilette SW et al. Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland primary prevention study: a nested case-control study. Lancet. 2007;369:107–114.
Panayiotou A et al. Leukocyte telomere length is associated with measures of subclinical atherosclerosis. Atherosclerosis. 2010;211(1):176–181.
Willeit P et al. Cellular aging reflected by leukocyte telomere length predicts advanced atherosclerosis and cardiovascular disease risk. Arterioscler Thromb Vasc Biol. 2010;30:1649–1656.
Jaffer FA, Libby P, Weissleder R. Optical and multimodality molecular imaging: insights into atherosclerosis. Arterioscler Thromb Vasc Biol. 2009;29:1017–1024.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer-Verlag London Limited
About this chapter
Cite this chapter
Kiechl, S., Werner, P., Knoflach, M., Willeit, J. (2011). Subclinical Atherosclerosis, Markers of Inflammation, and Oxidative Stress. In: Nicolaides, A., Beach, K., Kyriacou, E., Pattichis, C. (eds) Ultrasound and Carotid Bifurcation Atherosclerosis. Springer, London. https://doi.org/10.1007/978-1-84882-688-5_28
Download citation
DOI: https://doi.org/10.1007/978-1-84882-688-5_28
Published:
Publisher Name: Springer, London
Print ISBN: 978-1-84882-687-8
Online ISBN: 978-1-84882-688-5
eBook Packages: MedicineMedicine (R0)